Back to catalogue
№ 088 37 filings · 2021-08-27 → 2026-09-11

BRITISH SMALLER COMPANIES VCT2 PLC

BSC
Financial Services Share price 49.40p Market cap £188m Overall fit 260 /1000

Wrong vehicle for the strategy: only diluted, indirect AI exposure through 40+ small unquoted holdings; zero operating leverage at the fund level (management fee scales with NAV, incentive fee taxes upside); shares trade at NAV so no valuation cushion. Strong balance sheet and tax-relief-driven yield case for a different type of investor, but a poor fit for AI-receiver + operating-leverage strategy.

Fair value range 50p–55p Mid case · £201m
Absolute upside +6.7% vs current market cap
Conviction 4/5 confidence in fair call
Supports the call
  • NAV is unambiguous methodology for a VCT and is audit-quality disclosed at 52.25p
  • Realisation track record (Teraview 8.2x, Displayplan 9.6x, ACC 4.8x, Deep-Secure 7.7x) validates NAV marks
  • Shares trade essentially at NAV, so little residual re-rating risk in either direction
Limits the call
  • Level 3 private-company multiples can move sharply — H1 2026 saw £2.6m of downward marks on 5 holdings
  • Concentration in Matillion, whose carrying value has fallen >45% from peak
Methodology

NAV per share (published, IPEV-guideline Level 3 marks)

In one line · bull case

A well-run, cash-rich UK VCT trading at NAV that offers tax-advantaged yield and a diversified portfolio of small unquoted tech — but delivers only diluted AI exposure and zero operating leverage.

In one line · biggest risk

Continued revenue-multiple compression on legacy SaaS holdings from AI-disruption fears erodes NAV faster than realisations and new investments can replace it.

Drivers
AI beneficiary 35 /100
A few AI-native holdings (Xapien, Summize, Biorelate, Stormharvester) but legacy SaaS names in the portfolio are being marked down on AI-disruption fears — net negligible.
Operating leverage 15 /100
VCT wrapper has no operating leverage; management fee scales with NAV and incentive fee taxes upside above the hurdle.
Earnings vs expectations 50 /100
Not enough data — VCTs do not publish forward NAV guidance and no analyst consensus exists.
Growth momentum 35 /100
NAV per share has drifted down over 5 years pre-dividend; portfolio revenue growth is offset by multiple compression.
Moat 30 /100
No structural moat — YFM's franchise and VCT tax status help, but any generalist VCT can compete for the same deals.
Earnings quality 65 /100
Clean IFRS 13/IPEV Level 3 disclosure with quarterly review; sensitivity table published; realisations broadly validate marks.
Management quality 65 /100
YFM has run these funds since inception with consistent disclosure and long-term dividend delivery; incentive-fee structure is standard for VCTs.
Cyclicality 40 /100
Underlying portfolio is UK small-cap tech, moderately exposed to venture-funding and software-multiple cycles.
Leverage 5 /100
Zero debt; £77m of cash and MMFs (~39% of NAV) — fortress balance sheet.
Value-trap signals · 3
  • Multi-year decline in NAV per share pre-dividend (63.5p → 52.25p)
  • Largest historic holding (Matillion) written down >45% from peak carrying value
  • Portfolio tail includes multiple holdings below cost (Sipsynergy 0.3x, Quality Clouds, Panintelligence)

BSC — British Smaller Companies VCT2 plc

Executive summary

BSC is a UK-listed venture capital trust that invests in unquoted UK growth businesses (predominantly application software, data and tech-enabled services) and is managed by YFM Equity Partners. Across the covered period the company has grown NAV per share only modestly — from 63.5p at 30 June 2021 to 52.25p at 30 June 2026 (with 94.75p of cumulative dividends paid) — as portfolio revenue-multiple compression, driven partly by market concerns that AI will disintermediate legacy SaaS names, has offset underlying revenue growth 2026-09-11 half-year. The single most important valuation point today is that BSC is a NAV-driven fund vehicle: the shares trade essentially at NAV (52.25p NAV vs. quoted 50p), so there is no discount to close and there is no operating leverage to any single portfolio outcome.

Fair value estimate

  • Methodology: NAV-based. For a VCT with 40+ Level 3 unquoted holdings valued using IPEV revenue/earnings multiples, NAV is the only defensible anchor. VCTs trade close to NAV because ~30% income tax relief on subscription creates persistent primary demand and boards operate share buy-back schemes at small discounts.
  • Anchor: 30 June 2026 NAV per share of 52.25p 2026-09-11 half-year, supported by ±3.8% IPEV sensitivity on Level 3 holdings.
  • Fair value range: 50p – 55p per share. Low end reflects post-period dividend of 1.5p and further multiple pressure; high end reflects the mgr's stated H2 uplift in software multiples and possible small M&A-driven realisations.
  • Implied market cap range: ~£191m – £210m on 382.2m shares in issue.
  • Vs. disclosed £191.1m mcap: essentially in the middle of the range. Upside/downside: ~0% to +10% on a per-share basis; capital-return case rests on future portfolio realisations plus dividends, not re-rating.

Sector context

Confirmed sector: Financial Services (ICB Financials) — specifically a Venture Capital Trust. Quality/growth/leverage profile differs materially from typical financial-sector peers: no operating leverage, no earnings cyclicality in the operating sense, £77m of cash and money-market funds (≈39% of NAV) plus zero debt (fortress balance sheet), and NAV volatility that comes from underlying private-company valuation marks rather than lending or trading spreads. Comparable listed peers: British Smaller Companies VCT plc (sister fund, same manager), Baronsmead VCTs, Octopus Titan VCT, Northern VCTs.

Investment thesis (3 bullets)

  • Fortress balance sheet and NAV-anchored pricing floor. At 30 June 2026 BSC held £77.2m of cash and money-market funds (weighted return 3.5%) against £119.6m of investments and no debt; annual dividends target ~5–7% of opening NAV and are largely funded by realisations/income, providing an actionable yield with tax relief on new money 2026-09-11 half-year.
  • Selective AI-native exposure inside the portfolio. Xapien (automated research/KYC), Summize (contract lifecycle w/ embedded AI), Biorelate (AI pharma research platform), Stormharvester (AI wastewater analytics) and DynaRisk (cyber) are all AI-embedded holdings, with Xapien and Summize both raising Series B rounds in H1 2026 at premium valuations — 13 of 26 revenue-based portfolio names grew >25% YoY, producing £4.4m of valuation gains 2026-09-11 half-year.
  • Realisation track record supports NAV credibility. Recent full exits include Teraview (8.2x cost, £1.8m proceeds), Displayplan (9.6x), ACC Aviation (4.8x, potentially 5.9x with earn-out), Springboard (4.1x IRR 23%) and Deep-Secure (7.7x IRR 23%) — evidence that headline NAV marks are broadly realisable 2026-09-11, 2024-09-12, 2022-11-04, 2021-09-10.

Key risks (3 bullets)

  • AI disruption to legacy SaaS holdings. The chair explicitly stated in September 2026 that "market concerns around the risk of AI impacting existing software solutions" caused revenue-multiple compression across the portfolio; H1 2026 saw £2.6m of downward marks on Matillion, AutomatePro, Force24, Quality Clouds and Panintelligence 2026-09-11 half-year. This is precisely the value-destruction pattern that concerns AI-focused investors.
  • Concentration in single positions with weakening trajectory. Matillion, historically the largest and most valuable holding, has been marked down from a peak carrying value of £27m (June 2021) to £14.4m (June 2026) despite continued investment — a >45% write-down that shows how private-company marks can move 2026-09-11, 2021-09-10.
  • Regulatory/tax-relief risk. The 2025 UK Budget reduced the initial VCT income-tax relief; if further reductions or scheme changes follow, primary-market demand — which underpins the "NAV floor" — could weaken, opening a discount 2026-09-11 half-year, inferred.

Operating leverage

Effectively zero from the investor's perspective. A VCT is a fund whose cost base is a management fee (1.5% of net assets, running at £1.75m half-yearly) plus admin (~£0.4m) plus a performance-related incentive fee triggered above a share-price total-return hurdle. Because the manager's fee scales directly with NAV, incremental NAV growth does not drop disproportionately to shareholders — the fee grows with it. The incentive fee actually creates negative operating leverage on the way up (20% of returns above hurdle to the manager). At the portfolio-company level, individual holdings like Summize or Xapien may possess significant operating leverage internally, but that leverage is diluted across 40+ holdings and captured only via revaluation gains in NAV. A 10–20% revenue beat at a single top-five holding would move NAV per share by less than 1p. There are no observable inflection points at the fund level — spare capacity, fixed R&D, network effects are not applicable to the VCT wrapper itself 2026-09-11 half-year.

Value-trap signals

  • Declining NAV per share trend: 63.5p (Jun 2021) → 61.5p → 61.6p → 59.3p → 57.1p → 54.4p → 52.25p (Jun 2026), before adding back cumulative dividends — the shrinkage reflects both distributions and multiple compression.
  • 20 years post the current portfolio-building phase, several holdings sit meaningfully below cost (Sipsynergy 0.3x, Wooshii near-zero exit, KeTech now £1.2m vs £2.0m cost after strong prior returns), indicating that "value above cost" (85%) hides tail risk on individual names.
  • Not a classic value trap — the vehicle is designed for tax-advantaged income, not capital appreciation, and NAV is broadly credible.

Earnings vs. expectations

VCTs do not publish quarterly earnings guidance or attract analyst consensus, so a beat/miss frame doesn't strictly apply. What the filings do show: management does not issue forward NAV guidance; H1 total-return outcomes were +0.5p (Jun 2025), -0.3p (Jun 2024), +0.1p (Jun 2023), +10.0p (Jun 2021), -0.65p (Jun 2026). No visible pattern of "beats" or "misses" against internal targets — the swings reflect underlying portfolio revaluations, chiefly Matillion. Treat this as a "not enough data" signal (score 50).

Conviction

Conviction: 4 (high) — that the shares are FAIRLY VALUED, not that they are attractive.

Anchors: (i) NAV is the appropriate methodology, disclosure is unambiguous and audit-quality; (ii) shares trade essentially at published NAV so there is minimal ambiguity in the fair-value call; (iii) realisation history validates NAV marks in broad terms. Caveats: (i) Level 3 marks rely on private-company multiples that can move sharply — the H1 2026 £2.6m negative revaluation shows this; (ii) my confidence is in the fair-value call, not in fund performance — direction of future NAV depends on unpredictable individual private-company outcomes.

Overall assessment for this investor

This is fundamentally the wrong vehicle for the stated strategy. The investor wants direct AI-receiver exposure with operating leverage; a VCT gives them dilute, indirect, fee-eroded exposure. Some portfolio companies (Xapien, Summize) are exactly the type of AI-embedded names the investor might want to own — but they are held here as small, illiquid positions inside a fund whose value is being dragged down by revenue-multiple compression on the legacy names, not lifted by AI adoption. There is no operating leverage at the fund level, no valuation discount to NAV to exploit, and the underlying beta to "AI winners" is materially diluted.

Filings consulted · 38

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-09-11Half Year Financial Report2026-09-11_9767719_half-year-financial-report.md0.90
  2. 2026-06-09Result OF Agm2026-06-09_9609575_result-of-agm.md0.30
  3. 2026-05-06Dividend Declaration2026-05-06_9553643_dividend-declaration.md0.30
  4. 2025-11-20Offer Update2025-11-20_9246512_offer-update.md0.68
  5. 2025-10-10Offer Update2025-10-10_9164325_offer-update.md0.68
  6. 2025-10-02Offer Update2025-10-02_9146180_offer-update.md0.68
  7. 2025-09-12Half Year Report2025-09-12_9103093_half-year-report.md0.58
  8. 2025-06-12Result OF Agm2025-06-12_8926595_result-of-agm.md0.20
  9. 2025-05-13Dividend Declaration2025-05-13_8875679_dividend-declaration.md0.20
  10. 2024-12-17Dividend Declaration2024-12-17_8614895_dividend-declaration.md0.20
  11. 2024-11-20Offer Update2024-11-20_8562340_offer-update.md0.52
  12. 2024-11-20Offer Update2024-11-20_8562341_offer-update.md0.52
  13. 2024-11-01Offer Update2024-11-01_8522676_offer-update.md0.52
  14. 2024-11-01Offer Update2024-11-01_8522677_offer-update.md0.52
  15. 2024-09-12Half Year Report2024-09-12_8412325_half-year-report.md0.41
  16. 2024-08-20Statement RE Nav And Proposed Fundraising2024-08-20_8374327_statement-re-nav-and-proposed-fundraising.md0.32
  17. 2024-08-20Statement RE Nav And Proposed Fundraising2024-08-20_8374328_statement-re-nav-and-proposed-fundraising.md0.32
  18. 2024-06-13Result OF Agm2024-06-13_8258186_result-of-agm.md0.14
  19. 2023-12-13Offer Update2023-12-13_7940439_offer-update.md0.36
  20. 2023-10-24Offer Update2023-10-24_7836227_offer-update.md0.36
  21. 2023-10-24Offer Update2023-10-24_7836226_offer-update.md0.36
  22. 2023-10-06Offer Update2023-10-06_7801445_offer-update.md0.36
  23. 2023-10-06Offer Update2023-10-06_7801443_offer-update.md0.36
  24. 2023-09-27Offer Update2023-09-27_7780670_offer-update.md0.36
  25. 2023-09-13Half Year Report2023-09-13_7751783_half-year-report.md0.23
  26. 2023-06-15Result OF Agm2023-06-15_7577568_result-of-agm.md0.07
  27. 2023-02-14Offer Update2023-02-14_7453378_offer-update.md0.20
  28. 2022-12-06Offer Update2022-12-06_7320114_offer-update.md0.20
  29. 2022-11-04Dividend Declaration2022-11-04_7293195_dividend-declaration.md0.07
  30. 2022-10-03Offer Update2022-10-03_7199232_offer-update.md0.20
  31. 2022-09-20Half Year Report2022-09-20_7369864_half-year-report.md0.23
  32. 2022-08-04Dividend Declaration2022-08-04_7009829_dividend-declaration.md0.07
  33. 2022-06-13Result OF Agm2022-06-13_6939201_result-of-agm.md0.07
  34. 2021-10-11Offer Update2021-10-11_6760400_offer-update.md0.20
  35. 2021-09-27Offer Update2021-09-27_6592023_offer-update.md0.20
  36. 2021-09-24Offer Update2021-09-24_6560481_offer-update.md0.20
  37. 2021-09-10Half Year Report2021-09-10_6823296_half-year-report.md0.09
  38. 2021-08-27Statement RE Net Asset Value And Fundraising2021-08-27_6693532_statement-re-net-asset-value-and-fundraising.md0.07

This research note was authored by a large language model after reading 37 regulatory filings published between 2021-08-27 and 2026-09-11. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.